
Novavax (NVAX) Stock Forecast & Price Target
Novavax (NVAX) Analyst Ratings
Bulls say
Novavax is poised for long-term success due to its strong pipeline of vaccine candidates targeting a wide range of diseases, backed by its novel vaccine technology and partnerships with major pharmaceutical companies. Recent data from the SNY-led H2H trial and third-party reviews suggest that Nuvaxovid, the company's COVID-19 vaccine candidate, may have a differentiated tolerability profile compared to mRNA vaccines. With positive sales predictions, strong partnerships, and a promising adjuvant technology in Matrix-M, Novavax has the potential for significant growth in the coming years.
Bears say
Novavax is heavily reliant on partnerships for value creation, which may not yield the desired returns and the success of their products hinges on regulatory approvals for which there are potential setbacks. Given the highly competitive nature of the vaccine market and the potential for the SARS-CoV-2 virus to be eradicated, the long-term growth outlook for this company may not be sustainable. Financially, the current sales of their COVID-19 vaccine, Nuvaxovid, are insignificant, and the company is still in the early stages of developing their pipeline products and is yet to generate significant revenue.
This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.
Novavax (NVAX) Analyst Forecast & Price Prediction
Start investing in Novavax (NVAX)
Order type
Buy in
Order amount
Est. shares
0 shares